Evidence map›Paper›PMID 32965782›Full record

ArticlePhysiological reports2020

Pharmacodynamic effects of the K

Sai Prasad N Iyer, Lawrence Lee, Lingyun Li

Open access · goldAbstract read
In one paragraph

Article in Physiological reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Pharmacodynamic effects of the KPhysiological reports · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sai Prasad N IyerMedical and Scientific Affairs, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA.ORCID 0000-0003-0544-7904
Lawrence LeeMedical and Scientific Affairs, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA.
Lingyun LiMedical and Scientific Affairs, Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, USA.
Vifor Pharma (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently described hyperkalemia (HK) animal models are typically acute and cause significant distress and mortality to the animals, warranting new approaches for studying chronic HK in a more appropriate clinical setting. Using the spontaneously hypertensive rat (SHR) model as a more relevant disease template, as well as surgical (unilateral nephrectomy), dietary (3% potassium [K

Indexed as

AldosteroneAnimalsHyperkalemiaHypertensionMaleNephrectomyPolymersPotassiumRatsRats, Inbred SHRAldosteronepatiromerPolymersPotassiumaldosteronechronic kidney diseasehyperkalemiapatiromer

Identifiers

PMID32965782
PMCPMC7510565
OpenAlexW3088397077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.